Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (LSE:0R1F) — Drug Manufacturers - General. Numero di borse in cui sono quotate le azioni della società: 6. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- bms.com
- Relazioni con gli Investitori
- bms.com/investors.html
- Settore
- Healthcare · Drug Manufacturers - General
- Sede Centrale
- PRINCETON, United States
- Amministratore Delegato
- Christopher S. Boerner
- Dipendenti
- 32 500
- Fondata
- 1989
- Azioni in Circolazione
- 2.04 Mld al 2026-07-22
- Flottante
- 2.04 Mld
- Capitalizzazione di Mercato
- 128.41 Mld USD
- Insider
- 0.1%
- Investitori Istituzionali
- 84.87%
- Settore (SIC)
- Pharmaceutical Preparations
- Forma Giuridica
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- Payout Ratio
- 54.9%
- FCF
- 11.4 Mld USD45%
- Debito
- 43.9 Mld USD3.1 anni di FCF
- Serie di Dividendi
- 54 a.
- Utili, FCF e dividendi pagati — per i 12 mesi fino a 30.06.2026 (l'ultimo rapporto dell'azienda).
Descrizione
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Borse e Ticker
| Borsa | Ticker | Valuta | Prezzo | Tipo |
|---|---|---|---|---|
| US USA Stocks | BMY principale | USD | 59.58 -0.20% | azioni ordinarie |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | azioni ordinarie |
| MI Borsa Italiana (Milan) | 1BMY secondaria | EUR | 53.13 +0.28% | azioni ordinarie |
| MX Mexican Stock Exchange | BMY secondaria | MXN | 1 088.5 +1.73% | azioni ordinarie |
| VI Vienna Stock Exchange | BMYS secondaria | EUR | 52.98 +0.34% | azioni ordinarie |
| XETRA Xetra | BRM secondaria | EUR | 53.04 +0.89% | azioni ordinarie |
Dividendi
Bristol-Myers Squibb Company (BMY) paga dividendi trimestralmente. All'anno (12 mesi fino all'ultimo pagamento annunciato): 2.52 USD per azione (pagamenti: 4). Questo rappresenta circa il 4.23% del prezzo attuale delle azioni. In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 01.01.2027. Storia dei dividendi ininterrotta: 54 anni.
| Data Ex | Pagamento | Importo | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-10-02 | 2026-11-02 | 0.6300 USD | 1.1/4.2 % | trimestrale | US:BMY |
| 2026-07-02 | 2026-08-03 | 0.6300 USD | 1.1/4.2 % | trimestrale | US:BMY |
| 2026-04-02 | 2026-05-01 | 0.6300 USD | 1.1/4.2 % | trimestrale | US:BMY |
| 2026-01-02 | 2026-02-02 | 0.6300 USD | 1.1/4.2 % | trimestrale | US:BMY |
| 2025-10-03 | 2025-11-03 | 0.6200 USD | 1.0/4.2 % | trimestrale | US:BMY |
| 2025-07-03 | 2025-08-01 | 0.6200 USD | 1.0/4.1 % | trimestrale | US:BMY |
| 2025-04-04 | 2025-05-01 | 0.6200 USD | 1.0/4.1 % | trimestrale | US:BMY |
| 2025-01-03 | 2025-02-03 | 0.6200 USD | 1.0/4.1 % | trimestrale | US:BMY |
| 2024-10-04 | 2024-11-01 | 0.6000 USD | 1.0/4.0 % | trimestrale | US:BMY |
| 2024-07-05 | 2024-08-01 | 0.6000 USD | 1.0/≈4.0 % | trimestrale | US:BMY |
| 2024-04-04 | 2024-05-01 | 0.6000 USD | 1.0/2.0 % | trimestrale | US:BMY |
| 2024-01-04 | 2024-02-01 | 0.6000 USD | 1.0/1.0 % | trimestrale | US:BMY |
Notizie di Questa Settimana
Comunicati stampa dal sito web per investitori della società, aggiornati quotidianamente. I link conducono al sito web dell'azienda. I titoli sono nella lingua originale, come sul sito web dell'azienda.
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 Mln | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 Mln | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 Mln | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 Mln | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 Mln | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 Mln | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 Mln | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 Mln | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 Mln | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 Mln | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 Mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 Mln | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 Mln | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 Mln | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 Mln | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 Mln | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
